Get decades of growth at a discount with this healthcare investment trust

Healthcare is set for strong long-term expansion but looks cheap. That makes this investment trust worth buying, says Max King.

The re-rating of the US market has been led by technology-related companies, but the healthcare sector is lagging. According to Paul Major, fund manager of the BB Healthcare Trust (LSE: BBH), the S&P 500 Health Care Sector trades on a multiple of 18 times expected earnings, similar to where it has been in the last four or five years, but at a 20% discount to the overall market.

This is despite what Major calls “unquestionably, one of the greatest achievements of humanity – the delivery of six vaccines for a completely novel pathogen inside of 12 months”. This has not been an isolated example of innovation but part of an acceleration in medical advances encouraged by the relentless growth of demand. “Healthcare is a disproportionate beneficiary of rising wealth. As the world gets richer, healthcare spending per capita rises. Where else can one be certain that demand will rise continually?”

Relentless demand growth

“Moreover, healthcare spending correlates strongly with age and, as people live longer, the global population is ageing.” In the UK, healthcare spending for a 20-year-old averages £1,000 per annum but doubles at the age of 50, doubles again at 70 and reaches £10,000 at the age of 90. At 65, 80% of the population “have at least one chronic medical condition”.

The increase in healthcare spending is “unstoppable and uncorrelated to economic growth”. Meanwhile, Covid-19 has demonstrated “the need for investment in greater capacity and preventative medicine.” The problem is that somebody has to pay for this. 

In the US healthcare spending, 7% of GDP in 1980, has reached 18%. So governments have three options: “They can carry on as they are, allowing healthcare spending to eat all our marginal wealth creation. They can, as in the UK, choose to restrict the growth in healthcare costs to that of GDP, which leads to a chronically under-resourced system. Or they can change the system fundamentally.” Given the time horizons of politicians, they alternate between options one and two.

Improving efficiency 

BBH, however, aims to expose investors to the companies that will lead the inevitable transformation of healthcare. “In the UK, one in four healthcare appointments are deemed not to have been medically necessary while 25%-30% of frontline care staff time is spent on paperwork. Technologies, products and services that introduce efficiencies and better decision-making into the system offer tremendous value creation.”

The trust, now with £1bn of assets, trades at a small premium to net asset value (NAV) and yields 2.6%, paid out of capital. It was launched in 2016 to invest in a maximum of 35 listed companies without regard to geography, the size of companies or any benchmark index. The investment return over one year has been 58% and 113% since inception, 42% ahead of the MSCI World Health Care index. 

This puts BBH ahead of OrbiMed’s Worldwide Healthcare Trust and on a par with the Biotech Growth Trust in performance terms, although its portfolio sits between them in terms of its spread of investments and the relative emphasis on defensive versus growth stocks. “Innovation won’t be coming from the likes of Glaxo,” says Major. “Specialist managers like us” must find the stocks nobody has heard of. 

The most fruitful areas, he reckons, are information and healthcare technology, diagnostics, and specialist-drug companies. “In the long term, the stockmarket is rational and will reward the companies that generate higher levels of growth and cash generation.”

Investors, as Major says, “are paying less for growth in the healthcare sector than anywhere else. Healthcare has never looked cheaper

Recommended

Whether it’s cryptocurrencies or investment trusts, make sure you know what you’re investing in
Investment strategy

Whether it’s cryptocurrencies or investment trusts, make sure you know what you’re investing in

Many people scoff at cryptocurrency speculators pouring money into an asset they may barely understand. But the same could be said of investors in man…
26 Jan 2022
How to invest in energy and metals as tech stocks crash
Commodities

How to invest in energy and metals as tech stocks crash

It’s been a terrible week for stockmarkets. But not everything is crashing – “real” assets such as metals and energy are holding up well and should ha…
26 Jan 2022
Shareholder capitalism: the world’s most powerful asset manager wants you to have your say
ESG investing

Shareholder capitalism: the world’s most powerful asset manager wants you to have your say

Under shareholder capitalism, the owners of the companies the big fund managers invest in are us – yet our voice is rarely heard. Now one asset manage…
26 Jan 2022
Julian Brigden: markets are at a huge inflexion point
Investment strategy

Julian Brigden: markets are at a huge inflexion point

Merryn talks to Julian Brigden of Macro Intelligence 2 Partners about the unwinding of the US stockmarket's super-bubble, and the risks and opportunit…
25 Jan 2022

Most Popular

Shareholder capitalism: why we must return power to listed companies’ ultimate owners
Investment strategy

Shareholder capitalism: why we must return power to listed companies’ ultimate owners

Under our system of shareholder capitalism it's not fund managers, it‘s the individual investors – the company's ultimate owners – who should be telli…
24 Jan 2022
Three innovative Asian stocks to buy now
Share tips

Three innovative Asian stocks to buy now

Professional investor Fay Ren of the Cerno Pacific Fund highlights three of her favourite Asian stocks to buy now
24 Jan 2022
Ask for a pay rise – everyone else is
Inflation

Ask for a pay rise – everyone else is

As inflation bites and the labour market remains tight, many of the nation's employees are asking for a pay rise. Merryn Somerset Webb explains why yo…
17 Jan 2022